AstraZeneca Unloads Four NDAs to ANI Pharmaceuticals in $46.5M Deal Post author:Sam Post published:December 28, 2017 Post category:BioPharma ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace You Might Also Like Struggling Acorda is Exploring a Sale, Shares Jump January 7, 2018 Kitov Pharma Surges as Lead Drug Hits Goals in Phase III Test October 26, 2017 <b>International Society For The Study Of Celiac Disease</b> Release: Leading Immunologists Gather In New Delhi To Confront Celiac Disease August 31, 2017
<b>International Society For The Study Of Celiac Disease</b> Release: Leading Immunologists Gather In New Delhi To Confront Celiac Disease August 31, 2017
